Furthermore, the phase 3 randomized PARAGON-HF trial that enrolled patients with an LVEF ≥ 45% demonstrated a 13% non-significant reduction in total (first and recurrent) hospitalizations (primary endpoint; p = 0.06), and a 22% significant reduction in HF-related hospitalizations and CV-related death with ARNI versus angiotensin 2 receptor blocker (ARB) in a prespecified patient population with LVEF ≤ 57% [2]. The gene discussed is AGTR2; the disease is hydrops fetalis.